Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts

O. Kodet, B. Dvořánková, B. Bendlová, V. Sýkorová, I. Krajsová, J. Štork, J. Kučera, P. Szabo, H. Strnad, M. Kolář, Č. Vlček, K. Smetana, L. Lacina,

. 2018 ; 41 (5) : 2687-2703. [pub] 20180201

Language English Country Greece

Document type Case Reports, Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033352

Grant support
NV16-32665A MZ0 CEP Register
NV16-32665A MZ0 CEP Register
NV16-32665A MZ0 CEP Register

The incidence of malignant melanoma is rapidly increasing and current medicine is offering only limited options for treatment of the advanced disease. For B‑Raf mutated melanomas, treatment with mutation‑specific drug inhibitors may be used. Unfortunately, tumors frequently acquire resistance to the treatment. Tumor microenvironment, namely cancer‑associated fibroblasts, largely influence this acquired resistance. In the present study, fibroblasts were isolated from a patient suffering from acrolentiginous melanoma (Breslow, 4.0 mm; Clark, IV; B‑Raf V600E mutated). The present study focused on the expression of structural and functional markers of fibroblast activation in melanoma‑associated fibroblasts (MAFs; isolated prior to therapy initiation) as well as in autologous control fibroblasts (ACFs) of the same patient isolated during B‑Raf inhibitor therapy, yet before clinical progression of the disease. Analysis of gene transcription was also performed, as well as DNA methylation status analysis at the genomic scale of both isolates. MAFs were positive for smooth muscle actin (SMA), which is a marker of myofibroblasts and the hallmark of cancer stoma. Surprisingly, ACF isolated from the distant uninvolved skin of the same patient also exhibited strong SMA expression. A similar phenotype was also observed in control dermal fibroblasts (CDFs; from different donors) exclusively following stimulation by transforming growth factor (TGF)‑β1. Immunohistochemistry confirmed that melanoma cells potently produce TGF‑β1. Significant differences were also identified in gene transcription and in DNA methylation status at the genomic scale. Upregulation of SMA was observed in ACF cells at the protein and transcriptional levels. The present results support recent experimental findings that tumor microenvironment is driving resistance to B‑Raf inhibition in patients with melanoma. Such an activated microenvironment may be viable for the growth of circulating melanoma cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033352
003      
CZ-PrNML
005      
20181016115853.0
007      
ta
008      
181008s2018 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ijmm.2018.3448 $2 doi
035    __
$a (PubMed)29393387
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kodet, Ondřej $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
245    10
$a Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts / $c O. Kodet, B. Dvořánková, B. Bendlová, V. Sýkorová, I. Krajsová, J. Štork, J. Kučera, P. Szabo, H. Strnad, M. Kolář, Č. Vlček, K. Smetana, L. Lacina,
520    9_
$a The incidence of malignant melanoma is rapidly increasing and current medicine is offering only limited options for treatment of the advanced disease. For B‑Raf mutated melanomas, treatment with mutation‑specific drug inhibitors may be used. Unfortunately, tumors frequently acquire resistance to the treatment. Tumor microenvironment, namely cancer‑associated fibroblasts, largely influence this acquired resistance. In the present study, fibroblasts were isolated from a patient suffering from acrolentiginous melanoma (Breslow, 4.0 mm; Clark, IV; B‑Raf V600E mutated). The present study focused on the expression of structural and functional markers of fibroblast activation in melanoma‑associated fibroblasts (MAFs; isolated prior to therapy initiation) as well as in autologous control fibroblasts (ACFs) of the same patient isolated during B‑Raf inhibitor therapy, yet before clinical progression of the disease. Analysis of gene transcription was also performed, as well as DNA methylation status analysis at the genomic scale of both isolates. MAFs were positive for smooth muscle actin (SMA), which is a marker of myofibroblasts and the hallmark of cancer stoma. Surprisingly, ACF isolated from the distant uninvolved skin of the same patient also exhibited strong SMA expression. A similar phenotype was also observed in control dermal fibroblasts (CDFs; from different donors) exclusively following stimulation by transforming growth factor (TGF)‑β1. Immunohistochemistry confirmed that melanoma cells potently produce TGF‑β1. Significant differences were also identified in gene transcription and in DNA methylation status at the genomic scale. Upregulation of SMA was observed in ACF cells at the protein and transcriptional levels. The present results support recent experimental findings that tumor microenvironment is driving resistance to B‑Raf inhibition in patients with melanoma. Such an activated microenvironment may be viable for the growth of circulating melanoma cells.
650    _2
$a senioři $7 D000368
650    _2
$a fibroblasty asociované s nádorem $x účinky léků $x metabolismus $x patologie $7 D000072645
650    _2
$a metylace DNA $7 D019175
650    12
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a melanom $x farmakoterapie $x genetika $x patologie $7 D008545
650    _2
$a bodová mutace $7 D017354
650    _2
$a protoonkogenní proteiny B-raf $x antagonisté a inhibitory $x genetika $7 D048493
650    _2
$a nádory kůže $x farmakoterapie $x genetika $x patologie $7 D012878
650    _2
$a transkriptom $7 D059467
650    _2
$a nádorové buňky kultivované $7 D014407
650    12
$a nádorové mikroprostředí $7 D059016
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořánková, Barbora $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
700    1_
$a Bendlová, Běla $u Institute of Endocrinology, 11694 Prague, Czech Republic.
700    1_
$a Sýkorová, Vlasta $u Institute of Endocrinology, 11694 Prague, Czech Republic.
700    1_
$a Krajsová, Ivana $u Department of Dermatology and Venereology, General University Hospital, 12808 Prague, Czech Republic.
700    1_
$a Štork, Jiří $u Department of Dermatology and Venereology, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
700    1_
$a Kučera, Jan $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
700    1_
$a Szabo, Pavol $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
700    1_
$a Strnad, Hynek $u Institute of Molecular Genetics, Academy of Sciences of The Czech Republic, 14220 Prague, Czech Republic.
700    1_
$a Kolář, Michal $u Institute of Molecular Genetics, Academy of Sciences of The Czech Republic, 14220 Prague, Czech Republic.
700    1_
$a Vlček, Čestmír $u Institute of Molecular Genetics, Academy of Sciences of The Czech Republic, 14220 Prague, Czech Republic.
700    1_
$a Smetana, Karel $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
700    1_
$a Lacina, Lukáš $u Institute of Anatomy, First Faculty of Medicine, Charles University, 12808 Prague, Czech Republic.
773    0_
$w MED00173213 $t International journal of molecular medicine $x 1791-244X $g Roč. 41, č. 5 (2018), s. 2687-2703
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29393387 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181016120350 $b ABA008
999    __
$a ok $b bmc $g 1340117 $s 1030346
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 41 $c 5 $d 2687-2703 $e 20180201 $i 1791-244X $m International Journal of Molecular Medicine $n Int. J. Mol. Med. $x MED00173213
GRA    __
$a NV16-29032A $a NV16-30954A $a NV16-32665A $p MZ0 $p MZ0 $p MZ0
GRA    __
$a NV16-29032A $a NV16-30954A $a NV16-32665A $p MZ0 $p MZ0 $p MZ0
GRA    __
$a NV16-29032A $a NV16-30954A $a NV16-32665A $p MZ0 $p MZ0 $p MZ0
LZP    __
$a Pubmed-20181008
Back

Find record

Citation metrics

Archiving options